For research use only. Not for therapeutic Use.
HP210(CAT: I040946) is a selective glucocorticoid receptor modulator (SGRM) that regulates glucocorticoid receptor (GR) activity, offering a more targeted approach to modulating inflammatory responses compared to traditional corticosteroids. It effectively inhibits the mRNA expression of IL-1β and IL-6, two key pro-inflammatory cytokines involved in immune regulation and inflammatory diseases. Due to its ability to modulate GR function while potentially minimizing systemic side effects, HP210 is most relevant to Inflammation & Immunology Research. It holds promise for studying and developing therapies for inflammatory conditions such as rheumatoid arthritis, autoimmune diseases, and chronic inflammatory disorders.
| Catalog Number | I040946 |
| CAS Number | 728039-52-9 |
| Synonyms | 4-[(4-oxo-2-sulfanylidene-1H-thieno[3,2-d]pyrimidin-3-yl)methyl]-N-(1-phenylethyl)benzamide |
| Molecular Formula | C22H19N3O2S2 |
| Purity | ≥95% |
| IUPAC Name | 4-[(4-oxo-2-sulfanylidene-1H-thieno[3,2-d]pyrimidin-3-yl)methyl]-N-(1-phenylethyl)benzamide |
| InChI | InChI=1S/C22H19N3O2S2/c1-14(16-5-3-2-4-6-16)23-20(26)17-9-7-15(8-10-17)13-25-21(27)19-18(11-12-29-19)24-22(25)28/h2-12,14H,13H2,1H3,(H,23,26)(H,24,28) |
| InChIKey | AJJBGZJAGZSMJI-UHFFFAOYSA-N |
| SMILES | CC(C1=CC=CC=C1)NC(=O)C2=CC=C(C=C2)CN3C(=O)C4=C(C=CS4)NC3=S |
